Abstract:e16238 Background: Tumor with neuroendocrine differentiation (NED) has been verified in non-neuroendocrine organ adenocarcinomas. However, the incidence of NED in various studies varies greatly due to the different selection and criteria of NED markers. Further analysis of large clinical samples is still needed to reveal its biological characteristics and clarify the diagnosis and treatment of NED. Methods: From January 2017 to June 2018,a total of 450 histopathological samples were collected and analyzed retrospectively from patients with multiple malignant cancers, including gastric cancer (GC), colorectal cancer (CRC), lung cancer, breast cancer and prostate cancer treated in Cancer Hospital, Chinese Academy of Medical Sciences. Immunohistochemical staining for NED markers such as synaptophysin (Syn), chromogranin A (ChrA), and neural cell adhesion molecule (CD56) were performed to explore the incidence of different cancer types. Furthermore, NED or non-NED patients were evaluated comparatively in terms of pathological characteristics and prognosis. Results: Up to February 6, 2023, 129 CRC and GC samples were measured. 9 (15.3%) of 59 CRC patients were positive for NED markers, including 7 cases of Syn (+), 6 cases of ChrA (+) and 2 cases of CD56 (+). Moreover, 4 (6.8%) of 59 patients were positive for at least 2 NED markers in CRC. 18 (52.9%) of 34 gastric signer ring cell carcinoma patients were positive for NED markers, including 15 cases of Syn (+) and 14 cases of ChrA (+). Meanwhile, 10 (27.8%) of 36 gastric tubular adenocarcinoma patients were positive for NED markers, including 6 cases of Syn (+) and 10 cases of ChrA (+). Particularly, 17 (24.3%) (11/6, signer ring cell carcinoma/ tubular adenocarcinoma) of 70 GC patients were positive for at least two NED markers. Conclusions: NED is widely present in colorectal cancer and gastric cancer, especially in gastric signer ring cell carcinoma. The encouraging outcomes of the NED prevalence rate may shed light on the individualized treatments for patients with carcinomas. Further explorations are needed in the following research. [Table: see text]

Neuroendocrine Markers in Adenocarcinomas: an Investigation of 356 Cases.

Study of Neuroendocrine Markers in 356 Cases of Adenocarcinomas

Adjuvant Chemotherapy for Patients with Gastric Neuroendocrine Carcinomas or Mixed Adenoneuroendocrine Carcinomas.

Prognostic Significance of Neuroendocrine Differentiation in Colorectal Adenocarcinoma after Radical Operation: a Meta-Analysis.

[Association of Neuroendocrine Differentiation with Progression and Prognosis of Gastric Adenocarcinoma].

Prognostic Analysis of Neuroendocrine Component in Colorectal Adenocarcinoma

The Expression of Chromogranin A, Syanptophysin and Ki67 in Detecting Neuroendocrine Neoplasma at High Grade Colorectal Adenocarcinoma

Neuroendocrinology of Adrenalcortical Tumors: a Primary Study

Pathologic exploration of neuroendocrine differentiation in carcinomas.

Epidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohorts.

Clonality Analysis of Neuroendocrine Cells in Gastric Adenocarcinoma.

Clinical value of neuroendocrine markers for neoadjuvant chemotherapy response in patients with non-small-cell lung cancer(NSCLC)

Endocrine cells in colorectal adenocarcinomas: Incidence, hormone profile and prognostic relevance

Detection and Clinicopathologic Significance of Microsatellite Alteration and P53 Mutation of Neuroendocrine Cells in Colorectal Adenocarcinoma

Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract: A single-institute study of 43 cases

Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications

Abstract 4630: Clinical and epidemiological profile of neuroendocrine differentiation- A hospital-based retrospective study

Clinicopathological Characteristics and Prognosis of Gastrointestinal Cancer with Neuroendocrine Differentiation.

The Clinical Significance of Neuroendocrine Differentiation in T3-T4 Node-Negative Colorectal Cancer

[Preliminary Study of Neuroendocrine Differentiation and Its Mechanism in Ovarian Epithelial Tumors].

Biological Characteristics of Breast Carcinomas with Neuroendocrine Cell Differentiation